News & Announcements
-
Start of Trading on the OTCQB Venture Market
/**/ RNS Number : 3752K IQ-AI Limited 01 September 2021 September 1, 2021 IQ-AI Limited (“IQ-AI” or the “Company”) IQ-AI shares to commence trading on the OTCQB Venture Market in the United States IQ-AI Limited (LSE: IQAI) is pleased to announce that the Company’s ordinary shares will today begin trading on the
-
Half Yearly Report
/**/ RNS Number : 0232K IQ-AI Limited 27 August 2021 27 August 2021 IQ-AI Limited (the “Company” or the “Group”) Half Yearly Report for the Period Ended 30 June 2021 Chief Executive’s Statement I am pleased to announce IQ-AI Limited’s unaudited financial results for the six months ended 30 June 2021. · Revenue £238,438
-
IQ-AI sponsors Phase 1 GBM treatment trial
IQ-AI finances Phase I trial evaluating Gallium Maltolate in treatment of Glioblastoma Multiforme Imaging Biometrics’ IB Clinic software used to assess performance IQ-AI Limited (LON:IQAI) — IQ-AI commits to funding a phase I clinical trial to evaluate the safety and efficacy of Gallium Maltolate (GaM) in the treatment of Glioblastoma Multiforme (GBM). Its Imaging Biometrics
-
IQ-AI announces 2020 results
Year highlighted by new products, new partnerships, regulatory clearances for LSN and StoneChecker, new development initiatives. Read full report.
-
IQ-AI’s Imaging Biometrics’ IB Neuro named standard
IQ-AI’s Imaging Biometrics’ IB Neuro brain tumor software named part of standard imaging protocol IQ-AI Limited (LON:IQAI) — The investment firm explains how IB’s brain tumour imaging software benefits patients and their treatment teams, and why IB Neuro was solely included as the image post-processing component of the new standardised imaging protocol for brain tumours.